Oculis Holding AG (OCS) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50.98%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.76, delivering a surprise of -58.33%.Over the last four quarters, the company has not b ...

ZUG, Switzerland, May 08, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the first quarter ended March 31, 2025 and provided an overview of the Company's progress. Riad Sherif M.D., Chief Executive Officer of Oculis: "We began 2025 with an exciting evolution of our portfolio, driven ...

R&D Day Key Highlights: Recent Clinical Highlights and Upcoming Milestones: The recent R&D Day (replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor's (OCS-05) positive results from the ACUITY trial in Acute Optic Neuritis OCS-01: DIAMOND Ph3 trials enrollment completed with over 800 patients randomized; topline results expected Q2 2026 for the firs ...

The market expects Oculis Holding AG (OCS) to deliver a year-over-year decline in earnings on flat revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss ...

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [4] Upcoming Conferences - Oculis will present at several investor conferences, including Bio€quity Europe from May 12-14, 2025, where CEO Riad Sherif will provide a company update on May 14 at 11am CET [1] - The company will also participate in the Bank of America Healthcare Conference from May 13-15, 2025, with CFO Sylvia Cheung engaging in a fireside chat on May 14 at 3pm PT [2] - Additional presentations include the H.C. Wainwright Annual BioConnect at Nasdaq on May 20, 2025, and the Stifel Virtual Ophthalmology Forum on May 27, 2025, both featuring updates from CFO Sylvia Cheung [2] Company Pipeline - Oculis has a differentiated pipeline of innovative product candidates, including OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease [4]

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [5] Upcoming Conferences - Oculis will present at several investor conferences, including Bio€quity Europe from May 12-14, 2025, where CEO Riad Sherif will provide a company update on May 14 at 11am CET [1] - The company will also participate in the Bank of America Healthcare Conference from May 13-15, 2025, featuring a fireside chat with CFO Sylvia Cheung on May 14 at 3pm PT [2] - Additional presentations include the H.C. Wainwright Annual BioConnect at Nasdaq on May 20, 2025, and the Stifel Virtual Ophthalmology Forum on May 27, 2025, both featuring updates from CFO Sylvia Cheung [2] Company Pipeline - Oculis has a differentiated pipeline that includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) [5]

Company Overview - Oculis Holding AG is a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [20] - The company is developing a differentiated pipeline of innovative product candidates, including OCS-01 for diabetic macular edema (DME) and Licaminlimab for dry eye disease (DED) [20] Upcoming Presentations - Oculis will present its late-stage pipeline at several key conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress [1][2][3] - The presentations will cover interim results from the DME AWARE Delphi Study and insights from the Phase 3 DIAMOND program regarding OCS-01 eye drops for DME [2][3] Product Details - OCS-01 is an investigational eye drop formulation designed to treat DME non-invasively, aiming to transform the treatment paradigm by providing an alternative to invasive methods like intravitreal injections [13][14] - Licaminlimab (OCS-02) is being developed as a topical biologic anti-TNFα eye drop for DED, with a focus on personalized treatment approaches based on genetic biomarkers [16][19] Market Context - DME currently affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [15] - DED impacts over 110 million people in G7 countries, with a significant portion of patients remaining unsatisfied with current treatment options [18][19]

Core Insights - Oculis Holding AG is presenting its innovative late-stage pipeline at major ophthalmology conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress [1][2][3] Pipeline Developments - The DME AWARE Delphi Study interim results will focus on unmet needs in diabetic macular edema (DME) patient management, with insights from the Phase 3 DIAMOND program on OCS-01 eye drops [2][7] - OCS-01 is being developed as the first non-invasive treatment for DME, addressing the need for earlier intervention and for patients who do not respond adequately to current treatments [2][13] - Licaminlimab (OCS-02) is being investigated for dry eye disease (DED) and has shown positive results in Phase 2 trials, with a genetic biomarker identified to predict patient response [3][16] Conference Presentations - Oculis will showcase its developments at the following events: - Eyecelerator 2025 on May 2, 2025, featuring TKI and Drug Delivery [4] - ARVO Annual Meeting on May 5, 2025, presenting interim results of the DME AWARE Delphi Study [7] - Retina World Congress on May 8, 2025, discussing Licaminlimab in DED treatment [7] Market Context - DME currently affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [15] - DED impacts over 110 million people in G7 countries, with a significant portion of patients remaining unsatisfied with current treatment options [18][19] Company Overview - Oculis is a biopharmaceutical company focused on addressing significant unmet medical needs in ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for DME and Licaminlimab for DED [20]

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01. The issuance comprises 589,974 registered shares, reflecting the settlement of 310,941 shares issued in connection with the exercise of equity awards under the Company’s Stock Option and Incentive Plan Regulation and 279,033 shares issued through EBAC warran ...

Core Points - Oculis Holding AG announces the continuation of the Ramin Tadayoni Award in collaboration with EURETINA to honor the legacy of Professor Tadayoni, focusing on innovative research in retinal diseases [1][2] - The award provides €30,000 for research support and an additional €5,000 for the candidate, aimed at postgraduate scholars in retina research, with applications open until May 12, 2025 [3] - The inaugural recipient of the award in 2024 was Dr. Andrea Govetto, who is developing a computational model for macular edema [4] Company Overview - Oculis is a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema, Privosegtor for acute optic neuritis, and Licaminlimab for dry eye disease [6] - The company is headquartered in Switzerland and operates in the U.S. and Iceland, led by an experienced management team supported by international healthcare investors [6]